ReviewThe oncologist2012
Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.
Review in The oncologist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Pooled it
- Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Critical reviews in oncology/hematology · 2013Pooled it
- Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT.Nutrition and cancer · 2021Trial
- Trial
- Review
- Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy.World journal of clinical oncology · 2025Article
- Vitamins in the Pathogenesis of Prostate Cancer: Implications for Prevention and Therapeutic Support.International journal of molecular sciences · 2025Review
- Cancer treatment-induced bone loss.The Korean journal of internal medicine · 2024Review
- Article
- Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models.International journal of molecular sciences · 2023Review
- Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.Journal of bone and mineral metabolism · 2023Review
- A Narrative Review of the Safety of Anti-COVID-19 Nutraceuticals for Patients with Cancer.Cancers · 2021Review
- Canadian Urological Association best practice report: Bone health in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Review
- Exercise and Nutritional Approaches to Combat Cancer-Related Bone and Muscle Loss.Current osteoporosis reports · 2020Review
- Bone Health in Men with Prostate Cancer: Review Article.Current osteoporosis reports · 2019Review
- Epidemiology of Prostate Cancer.World journal of oncology · 2019Review
- Cancer- and Chemotherapy-Induced Musculoskeletal Degradation.JBMR plus · 2019Review
- Cancer Treatment and Bone Health.Calcified tissue international · 2018Review
- Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.Prostate cancer and prostatic diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLoss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups.
methodsWe reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy.
resultsWhether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density.
conclusionThe doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.